Welcome to the international HTA database
Showing [19518 Records] Selected Records [0 Hits] [Clear]
Year | Source | Title | |
---|---|---|---|
2015 | Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) | [Bioquell airborne disinfection system] | |
2014 | Basque Office for Health Technology Assessment (OSTEBA) | [Bioresorbable peripheral stents] | |
2006 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Bisphosphonates as treatment for breast cancer] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [Bladder tumor antigen test] | |
2008 | Haute Autorite de sante (HAS) | [Bladder volume measurement with portable ultrasound device] | |
2011 | The Swedish Council on Health Technology Assessment (SBU) | [Bleeding peptic ulcer] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Blinatumomab - assessment according to §35a (para. 1, sentence 10) Social Code Book V] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Blinatumomab (acute lymphoblastic leukaemia) - assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)] | |
2005 | Finnish Office for Health Care Technology Assessment (Finohta) | [Blood glucose self-monitoring in diabetes management] | |
2012 | The Swedish Council on Health Technology Assessment (SBU) | [Blood test for early diagnosis of Alzheimer's disease] | |
2019 | Andalusian Health Technology Assessment Area (AETSA) | [Blood test for the early diagnosis of pancreatic cancer. CancerSEEK] | |
2011 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Boceprevir - Benefit assessment according to §35a Social Code Book V (dossier assessment)] | |
2012 | German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) | [Bone graft substitutes in traumatology] | |
2018 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Bone marrow stem cell therapy for orthopedic conditions] | |
2013 | Haute Autorite de sante (HAS) | [Bone substitutes] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Bosutinib: assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)] | |
2011 | Andalusian Health Technology Assessment Area (AETSA) | [Botulinum toxin A in the treatment of morbid obesity] | |
2011 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Botulinum toxin for the treatment of headache] | |
2018 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Botulinum toxin in adult patients with dystonia] | |
2011 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Botulinum toxin use in adults and children with urinary tract function disorders] | |
1999 | Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) | [Brachytherapy and prostate cancer] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [BRAF gene mutation analysis] | |
2011 | Committee for New Health Technology Assessment (CNHTA) | [BRAF Gene, Mutation(Peptide Nucleic Acid Mediated Real-time PCR Clamping Method)] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [BRAF V600E mutation] | |
2011 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Brain injury rehabilitation - a health technology assessment] | |
2009 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [BRATS 08: Drug-eluting stents and bare-metal stents in the treatment of coronary artery disease] | |
2009 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [BRATS 09: Statins for the prevention of cardiovascular events] | |
2009 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [BRATS 10: Rituximab in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL)] | |
2010 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [BRATS 11: Positron Emission Tomography (PET) in the diagnosis, staging and restaging of patients with colorectal cancer] | |
2010 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [BRATS 12: Clinical strategies for smoking cessation] | |
2010 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [BRATS 13: The use of insulin glargine and insulin detemir to control type 1 diabetes mellitus] | |
2013 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Bravo pH monitoring in gastroesophageal reflux] | |
2013 | Andalusian Health Technology Assessment Area (AETSA) | [Breast cancer ablation with radiofrequency. Systematic review] | |
2013 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brentuximab Vedotin - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brentuximab vedotin (Hodgkin lymphoma with an increased risk of relapse or progression) - assessment according to § 35a (para. 1, sentence 10) Social Code Book V] | |
2013 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Brentuximab vedotin for Hodgkin´s lymphoma] | |
2015 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma] | |
2020 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42] | |
2020 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brivaracetam - addendum to commission A16-08] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brivaracetam - benefit assessment according to §35a Social Code Book V] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Brodalumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V] | |
2021 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Brolucizumab in neovascular age-related macular degeneration] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [Bronchial provocation test] | |
2021 | Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) | [Bronchial thermoplasty in severe asthma] | |
2012 | Basque Office for Health Technology Assessment (OSTEBA) | [Budget impact analysis of a telemedicine procedure in quality assurance programs for spirometry in patients with COPD] | |
2012 | Institut national d'excellence en sante et en services sociaux (INESSS) | [Budget impact analysis of increasing kidney transplantation in Québec] | |
2014 | Institut national d'excellence en sante et en services sociaux (INESSS) | [Building planning and infection control: hand hygiene dispensers and individual bathrooms in residential and long-term care centres] | |
2009 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Bupropion, mirtazapine, and reboxetine in the treatment of depression] | |
2010 | National Evidence-based Healthcare Collaborating Agency (NECA) | [Burden of irritable bowel syndrome in Korea] | |
2013 | Haute Autorite de sante (HAS) | [Bypass prostheses] | |
2012 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Bypass surgery performed with or without the use of heart-lung machine] | |
2011 | Committee for New Health Technology Assessment (CNHTA) | [C-11-acetate positron emission tomography, positron emission tomography/computed tomography] | |
2020 | Andalusian Health Technology Assessment Area (AETSA) | [C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections] | |
2012 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Cabazitaxel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2015 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Cabazitaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer not responding to docetaxel] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Cabozantinib - assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment)] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Cabozantinib (renal cell carcinoma) - addendum to order A16-69] | |
2018 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Cabozantinib (renal cell carcinoma) - benefit assessment according to §35a Social Code Book V] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V] | |
2005 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Caesarean section on maternal request: a health technology assessment] | |
2015 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Calreticulin gene mutation testing in myeloproliferative neoplasms] | |
2011 | Committee for New Health Technology Assessment (CNHTA) | [Camera manipulating robot assisted endoscopic surgery] | |
2019 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Canagliflozin, empagliflozin and dapagliflozin (SGLT-2) for patients with type 2 diabetes] | |
2019 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Canagliflozin, empagliflozin and dapagliflozin in type 2 diabetes patients] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Canagliflozin: benefit assessment according to § 35a Social Code Book V (dossier assessment)] | |
2014 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)] | |
2013 | Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) | [Canaloplasty for open angle glaucoma] | |
2001 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Cancer of the colon and rectum - diagnosis and screening] | |
2017 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Cannabinoids in patients with autism spectrum disorders] | |
2005 | Andalusian Health Technology Assessment Area (AETSA) | [Cannabis therapeutic utility] | |
2020 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V] | |
2007 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Capsule endoscopies of the small intestine - a health technology assessment] | |
2010 | Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) | [Cardiac contractility modulation for heart failure- 2nd Update 2010] | |
2010 | Haute Autorite de sante (HAS) | [Cardiac markers in coronary disease and heart failure in outpatient medicine] | |
2006 | Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) | [Cardiac rehabilitation - a health technology assessment: evidence from the literature and the DANREHAB trial] | |
2005 | Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) | [Cardiac resynchronization therapy: multi-site pacemaker use] | |
2010 | Unidad de Evaluacion de Tecnologias Sanitarias (UETS) | [Cardiac resynchronization therapy. Economic evaluation] | |
2010 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Cardiac surgery registry. An international review] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [Cardio detect(h-FABP)] | |
2018 | Andalusian Health Technology Assessment Area (AETSA) | [Cardiopoietic stem cells for the treatment of heart failure secondary to myocardial ischemia] | |
2021 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Cardiopulmonary resuscitation in COVID-19 patients] | |
2008 | The Netherlands Organisation for Health Research and Development (ZonMw) | [Cardiovascular prevention at old ages, competing risks, competing costs, frailty and indirect medical costs] | |
2013 | Andalusian Health Technology Assessment Area (AETSA) | [CardioWest™ TAH-t. Total artificial heart] | |
2020 | Andalusian Health Technology Assessment Area (AETSA) | [Care model for women with endometriosis. Systematic review of clinical practice guidelines] | |
2017 | German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) | [Care needs assessment tools] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Carfilzomib - assessment according to §35a (para. 1, sentence 10) Social Code Book V] | |
2016 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Carfilzomib (multiple myeloma; combination with dexamethasone alone) – assessment according to § 35a (para.1, sentence 10) Social Code Book V] | |
2017 | Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) | [Carfilzomib (multiple myeloma) – benefit assessment according to §35a Social Code Book V] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [Caries diagnosis with laser fluorescence(Diagnodent)] | |
2011 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Carotid echo doppler for plaque area measurement in cardiovascular risk stratification] | |
2011 | Basque Office for Health Technology Assessment (OSTEBA) | [Case and control study: efficiency of psychoeducational treatment of the overload experienced by family members of bipolar patients] | |
2008 | The Netherlands Organisation for Health Research and Development (ZonMw) | [Case finding in osteoporosis, how to implement current guidelines? A randomized comparison of two implementation strategies in general practice] | |
2012 | The Swedish Council on Health Technology Assessment (SBU) | [Case finding, diagnosis and follow up of patients with affective disorders] | |
2012 | Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) | [Catalan arthroplasty register. 2nd report (data 2005-2010)] | |
2010 | The Swedish Council on Health Technology Assessment (SBU) | [Catheter ablation for atrial fibrillation (update)] | |
2005 | The Swedish Council on Health Technology Assessment (SBU) | [Catheter ablation of atrial fibrillation - early assessment briefs (Alert)] | |
2012 | Institute for Clinical Effectiveness and Health Policy (IECS) | [Catheter-directed mechanical thrombolysis in thromboembolic disease] | |
2008 | Committee for New Health Technology Assessment (CNHTA) | [CBFB/MYH11 rearrangement, Quantification [Real-time RT-PCR]] | |
2009 | Committee for New Health Technology Assessment (CNHTA) | [CD4 lymphocyte activity (bioluminescent assay)] |